EOLS Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of […] | ||
 Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | ||
 Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. | ||
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... Evolus Inc (EOLS) raises full-year guidance on strong portfolio growth and strategic expansion into skin quality with Profhilo partnership. | ||
 Evolus Q2 Earnings Call Highlights Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations. Globa | ||
 Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||